AbbVie, Inc. Johnson & Johnson Services, Inc., and Bristol - Myers Squibb Company are Dominating the U.S. Arthritis Market in 2021

The U.S. Arthritis Drugs Market is expected to grow with a CAGR of 10.2% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/us-arthritis-market

The U.S. arthritis drugs market has witnessed increased strategic developments owing to favorable market scenarios.    

The major players dealing in the U.S. arthritis market are introducing a strong range of products and adopting strategic initiatives such as acquisition, agreement, and new product launches into the market. This helped companies to maximize sales with an enhanced product portfolio.

For instance-

  • In January 2022, AbbVie Inc. announced that the company has received FDA approval for SKYRIZI (risankizumab-rzaa) for the treatment of adult psoriatic arthritis. This has helped the company to increase its global presence and expand its product portfolio as well

AbbVie Inc. is the dominating player in the U.S. arthritis market. Some of the other key players existing in the market include Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Amgen Inc., F. Hoffman-La Roche Ltd, Novartis AG, Pfizer Inc., UCB S.A., Sanofi, Flexion Therapeutics Inc., Celltrion Healthcare Co., Ltd., Swedish Orphan Biovitrum AB, Bio-Rad Laboratories, Inc., Anika Therapeutics, Inc., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Abbott, Apotex Inc., Samsung Bioepis (A Subsidiary of Samsung Biologics), Beckman Coulter Inc., among others.

AbbVie, Inc.

AbbVie, Inc. is headquartered in Illinois, U.S. The company was established in 2013. It has public ownership. The company focuses on discovering and delivering innovative medicines and products to solve serious health issues. The company has product categories including Immunology, Oncology, Neuroscience, Eye Care, Virology, and Women’s Health, out of which the market-focused category is Immunology.

The company is engaged in the continuous development of arthritis drugs.

For instance,

  • In December 2021, AbbVie Inc. announced that the company has received FDA approval for RINVOQ (upadacitinib) for active psoriatic arthritis. This has helped the company to increase its revenue and grow its products in the market

The company has a wide presence across North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The company has various subsidiaries such as AbbVie Aviation LLC (U.S.), AbbVie Biopharmaceuticals LLC (U.S.), AbbVie Bioresearch Center Inc. (U.S.), AbbVie Biotech Ventures Inc. (U.S.), and AbbVie Biotherapeutics Inc. (U.S.), among others.

Johnson & Johnson Services, Inc.

Johnson & Johnson Services, Inc. is headquartered in New Jersey, U.S.and was founded in 1886. It has public ownership. The company focuses on developing medicines and helping people with their contribution in major therapeutic areas. The company is dealing in various business segments, that is, consumer health, pharmaceutical, and medical devices, out of which the market-focused segment is pharmaceutical. The company has product categories cardiovascular & metabolic disease, immunology, infectious diseases & vaccines, neuroscience, oncology, and pulmonary hypertension, out of which the market-focused category is immunology.

The company is engaged in the continuous development of arthritis drugs.

For instance,

  • In July 2020, Johnson & Johnson Services, Inc. announced that FDA has approved the drug TREMFYA for use in the treatment of psoriatic arthritis. This has helped the company to increase its global presence and expand the product portfolio as well

The company has a wide presence across North America, South America, Europe, Middle East and Africa, Asia-Pacific. The company also has various subsidiary companies such Acclarent, Inc. (U.S.), Actelion Pharmaceuticals US, Inc. (U.S.), Akros Medical, Inc. (U.S.), Albany Street LLC (U.S.), ALZA Corporation (U.S.), among others.

Bristol - Myers Squibb Company

Bristol - Myers Squibb Company has its headquarters in New York, U.S. was founded in 1887. It has public ownership. The company focuses on discovering, developing, and delivering innovative medicines to help patients with serious diseases. This company has product categories including oncology, hematology, immunology, cardiovascular disease, out of which the market-focused category is immunology.

The company is engaged in the continuous development of arthritis drugs.

For instance,

  • In June 2019, Bristol-Myers Squibb Company announced that 80 adult patients with early rheumatic arthritis have shown higher efficacy responses when treated with ORENCIA (abatacept). This has helped the company to make footprints in the arthritis treatment market and gain more revenue from it

The company has a wide presence across the Americas, Europe, Middle East and Africa, Asia-Pacific. The company also has various subsidiary companies such as Bristol-Myers Squibb (Proprietary) Limited (South Africa), Bristol-Myers Squibb Trading Co.,Ltd (China), Bristol-Myers Squibb (Singapore) Pte.Limited, Bristol-Myers Squibb (Taiwan) Ltd., Bristol-Myers Squibb Ltd. (U.S.), among others.